Sugi Predict

Sugi Predict / Compounds / SCHEMBL2658882

SCHEMBL2658882

SCHEMBL2658882

O=C(Nc1ccc(OC(F)(F)F)cc1)NC(c1ccc(C(=O)O)cc1)C1CCC(C2CCCCC2)CC1

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 9/20 0.54
▸ FAAH O00519 4/20 0.54
▸ EPHX1 P07099 2/20 0.52
▸ PDE2A O00408 4/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ FPR2 P25090 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ TRPV1 Q8NER1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2658883 1.00 EPHX2 (0.54) EPHX2FAAHEPHX1PDE2AALDH1A1
SCHEMBL4258400 0.87 GCGR (0.54) EPHX2FAAH
SCHEMBL2659918 0.86 EPHX2 (0.54) EPHX2FAAHEPHX1PDE2AALDH1A1
SCHEMBL4091871 0.86 EPHX2 (0.54) EPHX2FAAHEPHX1PDE2AALDH1A1
SCHEMBL2659919 0.86 EPHX2 (0.54) EPHX2FAAHEPHX1PDE2AALDH1A1
SCHEMBL4085483 0.83 GCGR (0.53) EPHX2FAAH
SCHEMBL4095725 0.83 GCGR (0.57) EPHX2FAAH
SCHEMBL2653712 0.81 EPHX2 (0.53) EPHX2FAAHEPHX1PDE2AALDH1A1
SCHEMBL7132556 0.80 EPHX2 (0.44) EPHX2FAAHEPHX1PDE2AALDH1A1
SCHEMBL4096367 0.79 EPHX2 (0.53) EPHX2FAAHEPHX1PDE2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed
EP-1183229-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-03-06 — — EP disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR EPHX2 3463/4885FAAH 832/4885EPHX1 2751/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR EPHX2 3463/4885FAAH 832/4885EPHX1 2751/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR EPHX2 3463/4885FAAH 832/4885EPHX1 2751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.